Back to Search Start Over

Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance

Authors :
Luyao Wang
Yili Fan
Boxiao Chen
Jiawei Zhang
Luyu Yang
Xi Qiu
Huawei Jiang
Jinfan Li
Xibin Xiao
Liansheng Huang
Yang Xu
Source :
Frontiers in Oncology, Vol 13 (2024)
Publication Year :
2024
Publisher :
Frontiers Media S.A., 2024.

Abstract

Despite significant improvements in prognosis, a subset of patients with primary central nervous system lymphoma (PCNSL) remains at high risk for relapse. The treatment of relapsed and refractory (R/R) PCNSL remains a major clinical challenge. Herein, we present a 24-year-old patient with PCNSL who relapsed 4 years after initial diagnosis and subsequently became refractory to high-dose methotrexate (HD-MTX), temozolomide, whole brain radiation therapy (WBRT), ibrutinib, and lenalidomide. She received thiotepa with anti-programmed cell death protein 1 (PD-1) antibody and achieved partial remission and then underwent autologous stem cell transplantation (ASCT) with thiotepa-based conditioning. Post-transplant maintenance with thiotepa and anti-PD-1 at 3-month intervals resulted in a durable complete response (CR) in this case of R/R PCNSL. Our report highlights the important role of thiotepa in the treatment of patients with R/R PCNSL.

Details

Language :
English
ISSN :
2234943X
Volume :
13
Database :
Directory of Open Access Journals
Journal :
Frontiers in Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.6a63b6bdb8e1494bba76f734cc1925b0
Document Type :
article
Full Text :
https://doi.org/10.3389/fonc.2023.1333761